<DOC>
	<DOC>NCT02864095</DOC>
	<brief_summary>The purpose of this study is to compare the blood loss of intravenous and topical administration of low dose epinephrine plus combined administration of intravenous and topical tranexamic acid for primary total hip arthroplasty.</brief_summary>
	<brief_title>Intravenous Versus Topical Administration of Low Dose Epinephrine Plus Combined Administration of Intravenous and Topical Tranexamic Acid (TXA)for Primary Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>All patients between the ages of 20 and 75 who were diagnosed with as having osteoarthritis or osteonecrosis of the femoral head Scheduled for an elective primary total hip arthroplasty Those who were willing and able to return for followup over at least a 6month postoperative period Acute coronary syndrome &lt; 6 months Glaucoma,pheochromocytoma, thyrotoxicosis, digoxin intoxication, serum potassium &lt; 3.0 mmol, alcohol abuse, premenopausal women Current treatment with adenosine diphosphate (ADP) receptor antagonists, Factor Xa or thrombin inhibitors,heparin (excluding Low Molecular Weight Heparin (LMWH) for perioperative thromboprophylaxis), tricyclic antidepressants, or monoamine oxidaseï¼ˆMAO) or CatecholOmethyltransferase (COMT) inhibitors Patients with history of thromboembolic disease, bleeding disorder Patients with history of renal impairment, cardiovascular diseases (previous myocardial infarction, atrial fibrillation ) or cerebrovascular conditions (previous stroke or peripheral vascular surgery) Allergy to TXA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Arthroplasty, Replacement, Hip</keyword>
	<keyword>Epinephrine</keyword>
	<keyword>Tranexamic acid</keyword>
</DOC>